Adebrelimab plus chemotherapy after surgery for bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding adebrelimab to S-1 chemotherapy after surgery helps prevent bile duct cancer from coming back. It may be an option for people who have had their cancer completely removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove your bile duct cancer.
- You are between 18 and 75 years old.
- You are generally well (able to do daily activities).
- Your blood counts, liver and kidney function are good enough.
- You have not had prior immunotherapy (like checkpoint inhibitors).
- You are willing to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three medicines (adebrelimab, apatinib, and standard chemotherapy) for people with newly diagnosed bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if the combination can shrink the tumor and make it possible to remove later.
This trial tests a combination treatment for biliary tract cancer that is borderline resectable or locally advanced. It combines a chemotherapy infusions directly into the liver (HAIC) with an immunotherapy drug (adebrelimab) and a targeted therapy pill (lenvatinib), aiming to shrink the tumor enough to allow surgery.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This trial is for people with bile duct cancer who have had surgery to remove all visible cancer but are at high risk of it coming back. It tests whether adding two medications — adebrelimab (an immunotherapy) and capecitabine (a chemotherapy pill) — after surgery can help prevent the cancer from returning.
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.